NCT00140101

Brief Summary

The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stents and is a recognized standard of care.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,099

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started May 2005

Longer than P75 for phase_2

Geographic Reach
4 countries

92 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2005

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 30, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 1, 2005

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2007

Completed
4.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2012

Completed
Last Updated

January 10, 2012

Status Verified

January 1, 2012

Enrollment Period

2.3 years

First QC Date

August 30, 2005

Last Update Submit

January 6, 2012

Conditions

Keywords

drug eluting stentsstentsangioplastycoronary artery diseasetotal coronary occlusioncoronary artery restenosisstent thrombosisvascular diseasemyocardial ischemiacoronary artery stenosis

Outcome Measures

Primary Outcomes (1)

  • The primary endpoint is TVR (Target Vessel Revascularization). TVR is defined as any ischemia driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.

    at 9 months

Secondary Outcomes (1)

  • The major secondary endpoint is in-segment late loss as measured by QCA. In-segment late loss is defined as the difference between the post-procedure minimal luminal diameter (MLD) and the follow-up angiography MLD.

    at 9 months

Study Arms (2)

1

EXPERIMENTAL

ZoMaxx™ Drug-Eluting Stent System

Device: ZoMaxx™ Drug-Eluting Coronary Stent System

2

ACTIVE COMPARATOR

TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System

Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent

Interventions

Drug eluting stent implantation stent in the treatment of coronary artery disease.

1

Drug eluting stent implantation stent in the treatment of coronary artery disease.

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is ≥ 18 years old
  • Subject is eligible for percutaneous coronary intervention (PCI) and has a single lesion requiring treatment
  • Subject is an acceptable candidate for CABG
  • Clinical evidence of ischemic heart disease or a positive functional study
  • Documented stable angina pectoris
  • The target lesion is a single de novo coronary artery lesion with ≥50 and \<100% stenosis by visual estimate

You may not qualify if:

  • Female of childbearing potential. Female subjects must be medically or surgically sterile or diagnosed as post-menopausal (i.e. one year since final menstrual cycle.
  • Evidence of an acute myocardial infarction and/or CK-MB\>2x upper limit of normal within 72 hours of the intended treatment
  • Known allergies to the following: aspirin, clopidogrel (Plavix) or ticlopidine (Ticlid), heparin, stainless steel, tantalum, contrast agent (that cannot be adequately premedicated), paclitaxel or drugs similar to zotarolimus (ABT-578) (i.e. tacrolimus, sirolimus, everolimus)
  • A platelet count \<100,000 cells/mm3or \>700,000 cells/mm3; a WBC \<3,000 cells/mm3; or hemoglobin \<10.0g/dL
  • Acute or chronic renal dysfunction (creatinine \>2.0 mg/dl or \>150µmol/L)
  • Subject has had any previous or planned brachytherapy in the target vessel

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (92)

Huntsville Hospital

Huntsville, Alabama, 35801, United States

Location

ACS-Mesa General Hospital

Gilbert, Arizona, 85233, United States

Location

Foundation for Cardiovascular Medicine

La Jolla, California, 92037, United States

Location

Scripps Memorial Hospital

La Jolla, California, 92037, United States

Location

Sequoia Hospital

Redwood City, California, 94062, United States

Location

Stanford University Medical Center

Stanford, California, 94305, United States

Location

University of Colorado

Denver, Colorado, 80262, United States

Location

Hartford Hospital

Hartford, Connecticut, 06102, United States

Location

Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

Location

University of Florida Health Science Center

Gainesville, Florida, 32610, United States

Location

Univ of Florida Health Science Center Shands

Jacksonville, Florida, 32209, United States

Location

Florida Hospital

Orlando, Florida, 32803, United States

Location

Morton Plant Hospital

Safety Harbor, Florida, 34695, United States

Location

Emory Crawford Long Hospital

Atlanta, Georgia, 30308, United States

Location

Piedmont Hospital

Atlanta, Georgia, 30309, United States

Location

Emory Hospital

Atlanta, Georgia, 30322, United States

Location

St. Joseph's Hospital of Atlanta

Atlanta, Georgia, 30342, United States

Location

NE Georgia Medical Center

Gainesville, Georgia, 30501, United States

Location

Medical Center of Central GA (MCCG)

Macon, Georgia, 31201, United States

Location

Rush University Medical Center

Chicago, Illinois, 60612, United States

Location

OSF St. Francis Medical Center

Peoria, Illinois, 61614, United States

Location

St. John's Hospital and Memorial Medical Center

Springfield, Illinois, 62701, United States

Location

Clarion Health/Methodist Hospital

Indianapolis, Indiana, 46202, United States

Location

The Heart Center of IN, LLC

Indianapolis, Indiana, 46290, United States

Location

Genesis Medical Center

Davenport, Iowa, 52803, United States

Location

Iowa Heart Center/Methodist Hospital

Des Moines, Iowa, 50309, United States

Location

University of Iowa Hospital

Iowa City, Iowa, 52242-1081, United States

Location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

Central Baptist Hospital

Lexington, Kentucky, 40503, United States

Location

Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States

Location

St. Joseph Medical Center

Towson, Maryland, 21204, United States

Location

Brigham & Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

Cape Cod Research Institute

Hyannis, Massachusetts, 02601, United States

Location

St. John's Hospital

Detroit, Michigan, 48236, United States

Location

Northern Michigan Hospital

Petoskey, Michigan, 49770, United States

Location

William Beaumont Hospital

Royal Oak, Michigan, 48073, United States

Location

Abbott Northwestern Hospital

Minneapolis, Minnesota, 55407, United States

Location

Baptist Hospital Desoto

Southaven, Mississippi, 38761, United States

Location

Barnes Jewish Hospital

St Louis, Missouri, 63110, United States

Location

Our Lady of Lourdes Medical Center

Cherry Hill, New Jersey, 08103, United States

Location

St. Joseph's Hospital Health Center

Liverpool, New York, 13088, United States

Location

Lenox Hill Hospital

New York, New York, 10021, United States

Location

New York Presbyterian Hospital-Cornell

New York, New York, 10021, United States

Location

Columbia Presbyterian Hospital

New York, New York, 10032, United States

Location

St. Francis Hospital

Roslyn, New York, 11576, United States

Location

Novant Medical Group

Charlotte, North Carolina, 28204, United States

Location

Moses H. Cone Memorial Hospital

Greensboro, North Carolina, 27401, United States

Location

Wake Medical Hospital

Raleigh, North Carolina, 27610, United States

Location

Forsyth Medical Center

Winston-Salem, North Carolina, 27103, United States

Location

Wake Forest University Baptist Medical Center

Winston-Salem, North Carolina, 27157, United States

Location

Aultman Health Foundation

Canton, Ohio, 44710, United States

Location

The Christ Hospital

Cincinnati, Ohio, 45219, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Riverside Methodist Hospital

Columbus, Ohio, 43214, United States

Location

EMH Regional Medical Center

Elyria, Ohio, 44035, United States

Location

Oklahoma Heart

Oklahoma City, Oklahoma, 73120, United States

Location

Pinnacle Health at Harrisburg Hospital

Harrisburg, Pennsylvania, 17110, United States

Location

Hahnemann University Hospital Drexel University

Philadelphia, Pennsylvania, 19107, United States

Location

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

Location

Univ of Pittsburgh Medical Center Health System

Pittsburgh, Pennsylvania, 15213, United States

Location

Holy Spirit Hospital

Wormleysburg, Pennsylvania, 17043, United States

Location

Medical University of South Carolina (MUSC)

Charleston, South Carolina, 29425, United States

Location

Erlanger Medical Center

Chattanooga, Tennessee, 37403, United States

Location

St. Luke's Episcopal Hospital

Houston, Texas, 77030, United States

Location

Lubbock Heart Hospital

Lubbock, Texas, 79410, United States

Location

Intermountain Medical Center

Salt Lake City, Utah, 84103, United States

Location

Inova Fairfax Hospital

Falls Church, Virginia, 22031, United States

Location

Overlake Hospital Medical Center

Bellevue, Washington, 98004, United States

Location

North Cascade Cardiology / St. Joseph's Hospital

Bellingham, Washington, 98225, United States

Location

Swedish Medical Center

Seattle, Washington, 98104, United States

Location

Deaconess Medical Center

Spokane, Washington, 99204, United States

Location

Heart Clinics Northwest/ Sacred Heart Medical Center

Spokane, Washington, 99204, United States

Location

St. Luke's Medical Center

Milwaukee, Wisconsin, 53215, United States

Location

St. Vincent's Hospital Sydney

Darlinghurst, New South Wales, 2010, Australia

Location

Eastern Heart Clinic, The Prince of Wales Hospital

Randwick, New South Wales, 2031, Australia

Location

The Prince Charles Hospital

Chermside, Queensland, 4061, Australia

Location

The Princess Alexandra Hospital

Woolloongabba, Queensland, 4109, Australia

Location

Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia

Location

Monash Medical Center - Cardiovascular Research Centre

Clayton, Victoria, 03168-, Australia

Location

St. Vincent's Hospital

Fitzroy, 3065, Australia

Location

Liverpool Hospital

New South Wales, 2170, Australia

Location

RWTH Aachen

Aachen, 52074-, Germany

Location

Charité - Campus Benjamin Franklin

Berlin, Germany

Location

St.Johannes Krankenhaus

Dortmund, 44137, Germany

Location

UKE Hamburg - Universitätsklinikum Eppendorf

Hamburg, 20251-, Germany

Location

Uniklinik Homburg

Homburg, 66421, Germany

Location

Leipzig Heart Center

Leipzig, 04289, Germany

Location

Uniklinik Mainz - Johannes Gutenberg Universitat

Mainz, 55131-, Germany

Location

Krankenhaus Siegburg - Heart Center Siegburg

Siegburg, 53721, Germany

Location

Auckland City Hospital

Auckland, 1003, New Zealand

Location

Christchurch Hospital

Christchurch, New Zealand

Location

Related Publications (1)

  • Gray WA, Yeung AC, Cutlip DE, Popma JJ, Fitzgerald PJ, Williams DO, Heuer H, O'Shaughnessy CD, Overlie PA, Mann JT, Cannon LA, Hermiller JB, Henry TD, Whitbourn R, Stuckey TD, Midei MG, Coe J, Schwartz LB. A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial. Int J Cardiol. 2012 May 17;157(1):96-101. doi: 10.1016/j.ijcard.2011.05.061. Epub 2011 Jun 11.

MeSH Terms

Conditions

Coronary DiseaseCoronary Artery DiseaseCoronary RestenosisVascular DiseasesMyocardial IschemiaCoronary Stenosis

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive Diseases

Study Officials

  • Alan Yeung, M.D.

    Stanford University

    PRINCIPAL INVESTIGATOR
  • David Lee, M.D.

    Stanford University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 30, 2005

First Posted

September 1, 2005

Study Start

May 1, 2005

Primary Completion

September 1, 2007

Study Completion

January 1, 2012

Last Updated

January 10, 2012

Record last verified: 2012-01

Locations